Botulinum Toxin is one of 229 small molecule programs targeting Botulinum Toxin. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
350 competitors in Treatment
Botulinum Toxin
Dexilant
Alfenta
Niclocide
Hivid
Valium
Lotemax
Norpramin
Barhemsys
Clomid
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details